These findings provided the rationale for using PPARα ligands, i.e., the clinically approved fibrates, as add-on therapy in neurological disorders caused by a gain of function of nAChRs, such as in sleep-related hypermotor epilepsy (SHE, previously named nocturnal frontal lobe epilepsy, NFLE). This evidence concerns the gene PPARA and familial sleep-related hypermotor epilepsy.